Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial.
Manmeet S AhluwaliaLisa R RogersRekha ChaudharyHerbert NewtonAhmad OzairAtulya Aman KhoslaAndrew B NixonBonne J AdamsBen K SeonDavid M PeereboomCharles P TheuerPublished in: Communications medicine (2023)
Single-agent TRC105 lacks activity in bevacizumab-refractory GBM, possibly secondary to upregulated VEGF-A expression. Meaningful mOS in bevacizumab+TRC105 cohort warrants further trials to investigate efficacy of combination therapy.